Autolus Therapeutics plc - American Depositary Shares (NQ:AUTL)

1.450 -0.030 (-2.03%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 14, 2026 Add to My Watchlist

Price and Volume

Volume	3,005,274
Open	1.500
Bid (Size)	1.450 (200)
Ask (Size)	1.490 (600)
Prev. Close	1.480
Today's Range	1.400 - 1.530
52wk Range	1.175 - 2.700
Shares Outstanding	52,346,231
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 01, 2026

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics to Participate in Upcoming Investor Conference

June 25, 2026

From Autolus Therapeutics plc

Via GlobeNewswire

Performance

YTD	-22.5%	-22.5%
1 Month	-3.3%	-3.3%
3 Month	-2.0%	-2.0%
6 Month	+5.8%	+5.8%
1 Year	-45.3%	-45.3%

More News

Autolus Therapeutics Receives Prix Galien UK Award

June 12, 2026

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics to Participate in Upcoming Investor Conferences

May 27, 2026

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics (NASDAQ:AUTL) Posts Inline Q1 Results with First Positive Gross Margin, but Full-Year Guidance Slightly Below Consensus ↗

May 14, 2026

Via Chartmill

Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026

May 21, 2026

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus (AUTL) Q1 2026 Earnings Transcript ↗

May 18, 2026

Via The Motley Fool

Autolus Therapeutics Q1 Earnings Call Highlights ↗

May 14, 2026

Via MarketBeat

Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

May 14, 2026

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026

May 05, 2026

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction

April 29, 2026

From Autolus Therapeutics plc

Via GlobeNewswire

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Leads Shift Toward Pipeline-Driven Valuation in Biotech Sector

April 22, 2026

Via Investor Brand Network

Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition

April 22, 2026

Via Investor Brand Network

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 21, 2026

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics to Participate in Upcoming Investor Conferences

April 07, 2026

From Autolus Therapeutics plc

Via GlobeNewswire

Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition

April 22, 2026

From BioMedWire

Via GlobeNewswire

Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

March 27, 2026

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026

March 16, 2026

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics to Participate in Upcoming Investor Conferences

February 24, 2026

From Autolus Therapeutics plc

Via GlobeNewswire

The $71 Billion Cancer Shift: Why The FDA Is Speeding Up

February 05, 2026

From Equity Insider

Via GlobeNewswire

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 04, 2026

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026

January 12, 2026

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell ShuttleTM Platform

January 06, 2026

From Cellares Corp

Via Business Wire

Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform

January 06, 2026

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025

December 08, 2025

From Autolus Therapeutics plc

Via GlobeNewswire

Frequently Asked Questions

Is Autolus Therapeutics plc - American Depositary Shares publicly traded?

Yes, Autolus Therapeutics plc - American Depositary Shares is publicly traded.

What exchange does Autolus Therapeutics plc - American Depositary Shares trade on?

Autolus Therapeutics plc - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Autolus Therapeutics plc - American Depositary Shares?

The ticker symbol for Autolus Therapeutics plc - American Depositary Shares is AUTL on the Nasdaq Stock Market

What is the current price of Autolus Therapeutics plc - American Depositary Shares?

The current price of Autolus Therapeutics plc - American Depositary Shares is 1.450

When was Autolus Therapeutics plc - American Depositary Shares last traded?

The last trade of Autolus Therapeutics plc - American Depositary Shares was at 07/14/26 04:00 PM ET

What is the market capitalization of Autolus Therapeutics plc - American Depositary Shares?

The market capitalization of Autolus Therapeutics plc - American Depositary Shares is 75.90M

How many shares of Autolus Therapeutics plc - American Depositary Shares are outstanding?

Autolus Therapeutics plc - American Depositary Shares has 76M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.